Brief: Halozyme Wins Injunction Stopping Manufacture And Sale Of Merck's Keytruda SC In Multiple European Markets
BRIEF-Halozyme Wins Injunction Stopping Manufacture And Sale Of Merck's Keytruda SC In Multiple European Markets Oct 7 (Reuters) - Halozyme Therapeutics, Inc. HALO.O:
HALOZYME WINS INJUNCTION STOPPING MANUFACTURE AND SALE OF MERCK'S KEYTRUDA SC IN MULTIPLE EUROPEAN MARKETS
HALOZYME THERAPEUTICS - COURT ORDERS MSD BV TO STOP KEYTRUDA SC MANUFACTURE AND SALE IN EIGHT EUROPEAN COUNTRIES
HALOZYME THERAPEUTICS - INJUNCTION FORBIDS MSD FROM FACILITATING INFRINGEMENT BY AFFILIATES
HALOZYME THERAPEUTICS - COURT REJECTS MERCK'S ARGUMENTS THAT EP622 PATENT IS INVALID
HALOZYME THERAPEUTICS - IV VERSION OF KEYTRUDA REMAINS AVAILABLE AND NOT COVERED BY HALOZYME'S PATENT OR COURT INJUNCTION
Source text: ID:nPn3Y05TGa
Further company coverage: HALO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsBrief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines